GO:0018444 translation release factor complex: Components, Assembly and Research Methods, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0018444 (translation release factor complex) is a heterodimeric cellular component that mediates the release of a nascent polypeptide chain from the ribosome.
• The complex is composed of two release factors, typically RF1/RF2 and RF3 in prokaryotes, or eRF1 and eRF3 in eukaryotes, which cooperate to recognize stop codons and catalyze peptidyl-tRNA hydrolysis.
• Release factor recruitment and activation are enhanced by factors such as PABP, which stimulates stop codon recognition and release factor recruitment.
• Time-resolved cryo-EM has revealed the structural basis for release-factor activation during termination, showing conformational changes that drive catalysis.
• Defects in release factor function or associated factors can lead to ribosome stalling, mitochondrial translation defects, and diseases such as cancer and neurodegeneration.
• CRISPR-based models (knockout, point mutation, knock-in, overexpression) enable precise dissection of release factor complex components in human disease and basic translation research.
Description
The translation release factor complex (GO:0018444) is a heterodimeric protein complex that plays an essential role in the final step of protein synthesis: the release of the newly synthesized polypeptide chain from the ribosome. This complex is conserved across all domains of life, with prokaryotic and eukaryotic versions differing in their specific components but sharing the core function of stop codon recognition and peptidyl-tRNA hydrolysis. In prokaryotes, the complex typically consists of a class I release factor (RF1 or RF2) and a class II release factor (RF3), while in eukaryotes it comprises eRF1 and eRF3. The precise assembly and activation of this complex are critical for translational fidelity and cellular homeostasis. Research on the translation release factor complex has been accelerated by advances in structural biology, particularly time-resolved cryo-electron microscopy, which has captured the dynamic conformational changes that occur during release factor activation. Additionally, high-throughput assays such as fluorescence anisotropy have been developed to study release factor-dependent peptide release, facilitating mechanistic studies and nonsense suppressor screening. The complex is also implicated in ribosome-associated quality control, where factors like Vms1p act as release factors for stalled ribosomes. Dysregulation of translation termination has been linked to various human diseases, including mitochondrial disorders, cancer, and neurodegeneration. For example, loss of COX14 function leads to defective mitochondrial COX1 translation and ROS-induced inflammation, highlighting the importance of proper termination in mitochondrial gene expression. Similarly, the human mitochondrial translation factor TACO1 alleviates mitoribosome stalling at polyproline stretches, underscoring the role of release factors in resolving translation obstacles. Understanding the translation release factor complex is therefore essential for both basic biology and therapeutic development.
translation release factor complex At A Glance
| GO ID | GO:0018444 |
|---|---|
| GO term | translation release factor complex |
| Ontology | cellular_component |
| Synonym | eukaryotic peptide chain release factor, peptide chain release factor |
| Major function | Release of nascent polypeptide chain from the ribosome during translation termination |
| Complex type | Heterodimeric complex |
| Conserved in | Prokaryotes and eukaryotes |
| Key components | RF1/RF2 and RF3 in prokaryotes; eRF1 and eRF3 in eukaryotes |
| Associated factors | PABP enhances release factor recruitment and stop codon recognition |
What Is GO:0018444?
The translation release factor complex (GO:0018444) is defined as a heterodimeric complex involved in the release of a nascent polypeptide chain from a ribosome. It is a cellular component that functions at the termination step of translation, recognizing stop codons and catalyzing the hydrolysis of the peptidyl-tRNA bond to free the newly synthesized protein. This complex is also known by synonyms such as eukaryotic peptide chain release factor and peptide chain release factor.
Why Is translation release factor complex Important in Cell Biology?
The translation release factor complex is essential for terminating protein synthesis accurately and efficiently, preventing ribosome stalling and ensuring proteostasis. Its dysfunction can lead to a range of human diseases, including mitochondrial disorders, cancer, and neurodegenerative conditions. Moreover, understanding its mechanism provides insights into translational control and offers potential targets for therapeutic intervention, such as nonsense suppression therapies.
• Ensures proper termination of protein synthesis, preventing ribosome stalling and translational errors.
• Plays a critical role in mitochondrial gene expression, with defects linked to inflammation and metabolic disorders.
• Involved in ribosome-associated quality control, where release factors like Vms1p resolve stalled ribosomes.
• Dysregulation is associated with cancer and neurodegeneration, making it a potential therapeutic target.
• Enhances translational fidelity by preventing readthrough of stop codons.
• Structural studies provide a framework for designing small molecules that modulate termination.
• High-throughput assays enable screening for nonsense suppressors and mechanistic studies.
• CRISPR models allow precise manipulation of release factor genes to study their roles in disease.
What Happens During translation release factor complex?
Stop Codon Recognition
In simple terms: The release factor complex reads the stop signal on the mRNA.
The translation release factor complex recognizes stop codons (UAA, UAG, UGA) in the ribosomal A site. In prokaryotes, RF1 recognizes UAA and UAG, while RF2 recognizes UAA and UGA; in eukaryotes, eRF1 recognizes all three stop codons. This recognition is enhanced by factors such as PABP, which stimulates release factor recruitment and stop codon recognition.
Peptidyl-tRNA Hydrolysis
In simple terms: The complex cuts the bond between the protein and the tRNA.
Upon stop codon recognition, the release factor complex catalyzes the hydrolysis of the ester bond between the nascent polypeptide and the tRNA in the peptidyl transferase center of the ribosome. This reaction releases the completed protein. Time-resolved cryo-EM has revealed that conformational changes in the release factor drive this catalysis.
Release Factor Activation and Conformational Changes
In simple terms: The complex changes shape to become active.
Activation of the release factor involves a series of conformational changes, including the flipping of a conserved GGQ motif into the peptidyl transferase center. This process is regulated by the ribosome and associated factors, and has been visualized using time-resolved cryo-EM. The class II release factor (RF3/eRF3) facilitates the dissociation of the class I factor after hydrolysis.
Ribosome Recycling
In simple terms: After release, the ribosome is taken apart for reuse.
Following polypeptide release, the ribosome must be recycled. Ribosome recycling factor (RRF) and elongation factor G (EF-G) disassemble the termination complex, preparing the ribosome for a new round of translation. This step is crucial for preventing translational errors and maintaining cellular protein synthesis capacity.
Quality Control and Rescue
In simple terms: Special factors rescue stalled ribosomes.
When ribosomes stall, quality control pathways recruit release factors such as Vms1p to rescue them. Vms1p acts as a release factor for the ribosome-associated quality control complex, facilitating the degradation of aberrant polypeptides and recycling of ribosomes. This mechanism is important for proteostasis and is linked to diseases such as neurodegeneration.
Key Genes Involved in GO:0018444 translation release factor complex
The following genes encode components and regulators of the translation release factor complex across species.
| Gene | Major Role | Research Relevance |
|---|---|---|
| RF1 (prfA) | Prokaryotic class I release factor recognizing UAA/UAG | Model for stop codon recognition and peptidyl-tRNA hydrolysis |
| RF2 (prfB) | Prokaryotic class I release factor recognizing UAA/UGA | Studied for programmed frameshifting and termination |
| RF3 (prfC) | Prokaryotic class II release factor, GTPase | Facilitates dissociation of RF1/RF2 after release |
| eRF1 (ETF1) | Eukaryotic class I release factor recognizing all stop codons | Central to eukaryotic termination; implicated in cancer and neurodegeneration |
| eRF3 (GSPT1) | Eukaryotic class II release factor, GTPase | Regulates eRF1 activity and termination efficiency |
| PABP (PABPC1) | Poly(A)-binding protein, enhances release factor recruitment | Modulates stop codon recognition and termination |
| Vms1p (ANKZF1) | Release factor for ribosome-associated quality control | Rescues stalled ribosomes; linked to neurodegeneration |
| TACO1 | Mitochondrial translation factor alleviating mitoribosome stalling | Defects cause mitochondrial disease |
| COX14 | Mitochondrial translation factor for COX1 | Loss triggers ROS-induced inflammation |
| RRF (frr) | Ribosome recycling factor | Disassembles termination complex; prevents translational errors |
| EF-G (fusA) | Elongation factor G, also involved in recycling | Works with RRF in ribosome recycling |
| GGQ motif proteins | Catalytic motif in release factors | Essential for peptidyl-tRNA hydrolysis |
| eIF5A | Translation elongation factor with role in termination | Modulates release factor function |
| Dbp5 | RNA helicase involved in termination | Facilitates release factor recycling |
| Hbs1 | GTPase involved in ribosome quality control | Works with Dom34 in no-go decay |
| Dom34 (Pelota) | Release factor-like protein in no-go decay | Rescues stalled ribosomes |
| Rli1 (ABCE1) | ATPase involved in ribosome recycling | Essential for splitting ribosomes after termination |
How Is translation release factor complex Regulated?
The translation release factor complex is regulated at multiple levels. In eukaryotes, the GTPase activity of eRF3 is stimulated by eRF1 and the ribosome, and this is modulated by PABP, which enhances release factor recruitment and stop codon recognition. In prokaryotes, RF3 facilitates the dissociation of RF1/RF2 in a GTP-dependent manner. Additionally, ribosome recycling factor (RRF) and EF-G are required for disassembling the termination complex, and their activity is coupled to the release of the polypeptide. Quality control pathways, such as ribosome-associated quality control, recruit alternative release factors like Vms1p to resolve stalled ribosomes. Mitochondrial translation termination is regulated by factors such as TACO1 and COX14, which alleviate stalling at specific sequences.
translation release factor complex and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| COX14 | Mitochondrial dysfunction, ROS-induced inflammation | Knockout mouse or cell lines |
| TACO1 | Mitochondrial disease, mitoribosome stalling | Knockout or point mutation models |
| Vms1p (ANKZF1) | Neurodegeneration, impaired quality control | Knockout or overexpression in neuronal cells |
| eRF1 (ETF1) | Cancer, translational dysregulation | Knockdown or overexpression in cancer cell lines |
| eRF3 (GSPT1) | Cancer, termination efficiency | Point mutation or knockout models |
Mitochondrial Translation Defects and Inflammation
Defects in mitochondrial translation termination can lead to severe disorders. Loss of COX14 function causes defective mitochondrial COX1 translation, triggering ROS-induced inflammation in mouse liver. Similarly, mutations in TACO1, a mitochondrial translation factor, result in mitoribosome stalling at polyproline stretches and are associated with mitochondrial disease. These findings highlight the importance of proper release factor function in mitochondrial gene expression and cellular homeostasis.
Cancer and Neurodegeneration
Dysregulation of translation termination has been implicated in cancer and neurodegeneration. For example, eRF1 and eRF3 are overexpressed in some cancers, and their activity can affect the translation of oncogenes and tumor suppressors. In neurodegeneration, impaired ribosome quality control and release factor dysfunction contribute to the accumulation of aberrant proteins, as seen with Vms1p in ribosome-associated quality control. Targeting the release factor complex may offer therapeutic opportunities for these diseases.
Nonsense Suppression and Genetic Disorders
Nonsense mutations that introduce premature stop codons can be suppressed by modulating release factor activity. High-throughput assays for release factor-dependent peptide release have been developed to screen for nonsense suppressors, which could be used to treat genetic disorders caused by premature termination. Understanding the release factor complex is therefore crucial for developing therapies that promote readthrough of premature stop codons.
From translation release factor complex-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| What is the effect of release factor loss on global translation? | Knockout cell lines (e.g., eRF1, eRF3) |
| How do point mutations in the GGQ motif affect catalysis? | Point mutation knock-in models |
| Can a tagged release factor be used to study complex assembly? | Tagged knock-in (e.g., GFP or FLAG) |
| What is the impact of release factor overexpression on termination? | Overexpression cell lines |
| How does Vms1p rescue stalled ribosomes? | Knockout and overexpression models |
| What is the role of TACO1 in mitochondrial translation? | Knockout mouse models |
How to Study the translation release factor complex Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Ribo-seq | Ribosome occupancy and stalling at codon resolution | Global translation termination efficiency |
| Fluorescence anisotropy | Release factor-dependent peptide release | Nonsense suppressor screening |
| Time-resolved cryo-EM | Conformational changes during activation | Structural mechanism of release factors |
| Proteomics (AP-MS) | Protein-protein interactions | Identifying release factor complex partners |
| In vitro translation | Peptide release and termination efficiency | Mechanistic studies with mutant release factors |
| CRISPR screening | Gene essentiality and synthetic lethality | Identifying vulnerabilities in release factor mutants |
| Western blot | Protein expression levels | Validating knockout or overexpression |
| qRT-PCR | mRNA expression | Assessing transcriptional regulation |
Ribosome Profiling (Ribo-seq)
Ribo-seq provides a genome-wide snapshot of ribosome occupancy at codon resolution, allowing researchers to detect stalling at stop codons and assess the efficiency of translation termination. This method has been used to study the effects of release factor depletion or mutation on ribosome dynamics.
Fluorescence Anisotropy Assays
High-throughput fluorescence anisotropy assays have been developed to measure release factor-dependent peptide release from pretermination complexes. This technique enables mechanistic studies and screening for nonsense suppressors that modulate termination.
Time-Resolved Cryo-Electron Microscopy
Time-resolved cryo-EM captures transient conformational states during release factor activation, providing structural insights into the catalytic mechanism of peptidyl-tRNA hydrolysis. This method is powerful for visualizing dynamic processes in translation termination.
Proteomics and Interactomics
Affinity purification coupled with mass spectrometry can identify interacting partners of the release factor complex, revealing regulatory proteins and quality control factors. Such studies have helped map the network of proteins involved in termination and recycling.
How CRISPR Can Be Used to Study GO:0018444 translation release factor complex
Knockout
CRISPR knockout of release factor genes (e.g., eRF1, eRF3, Vms1p) enables researchers to study loss-of-function phenotypes, including effects on translation termination, cell viability, and disease models. For example, knockout of COX14 in mice leads to mitochondrial dysfunction and inflammation, and knockout of TACO1 causes mitoribosome stalling.
Point Mutation
Point mutations can be introduced into release factor genes to dissect specific residues involved in catalysis or regulation. For instance, mutations in the GGQ motif of release factors abolish peptidyl-tRNA hydrolysis, and CRISPR knock-in of such mutations allows functional studies in cells.
Knock-in
Knock-in of tagged release factors (e.g., GFP, FLAG) facilitates imaging and biochemical purification of the complex. This approach has been used to study the assembly and localization of release factors in cells.
Overexpression
Overexpression of release factors or their regulators can reveal gain-of-function phenotypes, such as increased termination efficiency or suppression of nonsense mutations. This is particularly useful for studying the role of eRF1 and eRF3 in cancer.
How EDITGENE Supports translation release factor complex Research
Researchers studying translation release factor complex-related genes often need to determine whether a candidate gene is causally involved in translation termination, disease progression, or therapeutic response. Precise genetic models are essential to validate mechanisms and identify targets.
Contact EDITGENE today to design your custom CRISPR model for translation release factor complex research.
Frequently Asked Questions About translation release factor complex
What is the translation release factor complex?
The translation release factor complex (GO:0018444) is a heterodimeric protein complex that releases the nascent polypeptide chain from the ribosome during translation termination.
What genes are involved in the translation release factor complex?
Key genes include RF1, RF2, RF3 in prokaryotes, and eRF1 (ETF1), eRF3 (GSPT1), PABP, Vms1p (ANKZF1), TACO1, and COX14 in eukaryotes.
What is the function of GO:0018444?
GO:0018444 functions in stop codon recognition and peptidyl-tRNA hydrolysis, releasing the completed protein from the ribosome.
How is the translation release factor complex regulated?
It is regulated by GTP hydrolysis, PABP-mediated enhancement of release factor recruitment, and quality control factors like Vms1p.
What diseases are associated with translation release factor complex dysfunction?
Diseases include mitochondrial disorders, cancer, neurodegeneration, and inflammation due to defective termination.
What methods are used to study the translation release factor complex?
Methods include Ribo-seq, fluorescence anisotropy, time-resolved cryo-EM, proteomics, and CRISPR screening.
Can CRISPR be used to study release factor genes?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models enable precise functional studies of release factor genes.
What is the role of eRF1 in translation termination?
eRF1 recognizes stop codons and catalyzes peptidyl-tRNA hydrolysis in eukaryotes.
How does Vms1p function in quality control?
Vms1p acts as a release factor for the ribosome-associated quality control complex, rescuing stalled ribosomes.
What is the clinical relevance of nonsense suppression?
Modulating release factor activity can suppress premature stop codons, offering therapeutic potential for genetic disorders.
Conclusion
The translation release factor complex (GO:0018444) is a central component of translation termination, ensuring accurate protein synthesis and cellular homeostasis. Its dysfunction is linked to a spectrum of human diseases, from mitochondrial disorders to cancer. Advanced structural and functional studies continue to unravel its mechanism, while CRISPR-based models provide powerful tools for dissecting its roles in health and disease.
References
- 1. Rodnina MV. 2018. Translation in Prokaryotes.. Cold Spring Harb Perspect Biol 10(9) PMID: 29661790
- 2. Brischigliaro M et al.. 2024. The human mitochondrial translation factor TACO1 alleviates mitoribosome stalling at polyproline stretches.. Nucleic Acids Res 52(16):9710-9726 PMID: 39036954
- 3. Ivanov A et al.. 2016. PABP enhances release factor recruitment and stop codon recognition during translation termination.. Nucleic Acids Res 44(16):7766-76 PMID: 27418677
- 4. Janosi L et al.. 1996. Dual functions of ribosome recycling factor in protein biosynthesis: disassembling the termination complex and preventing translational errors.. Biochimie 78(11-12):959-69 PMID: 9150873
- 5. Fu Z et al.. 2019. The structural basis for release-factor activation during translation termination revealed by time-resolved cryogenic electron microscopy.. Nat Commun 10(1):2579 PMID: 31189921
- 6. Ghelfi MD et al.. 2023. A High-Throughput Assay for In Vitro Determination of Release Factor-Dependent Peptide Release from a Pretermination Complex by Fluorescence Anisotropy-Application to Nonsense Suppressor Screening and Mechanistic Studies.. Biomolecules 13(2) PMID: 36830611
- 7. Zurita Rendón O et al.. 2018. Vms1p is a release factor for the ribosome-associated quality control complex.. Nat Commun 9(1):2197 PMID: 29875445
- 8. Aich A et al.. 2024. Defective mitochondrial COX1 translation due to loss of COX14 function triggers ROS-induced inflammation in mouse liver.. Nat Commun 15(1):6914 PMID: 39134548
